Introduction
Epidemiological data show an increased incidence of asthma in overweight or obese children and adults. The relative risk of incident asthma increases with increasing body mass, which has been associated with enhancement of asthma symptoms, airway hyperresponsiveness (AHR) and atopy 1) . Obesity is particularly important for severe asthma because more than 75% of asth matic individuals visiting the emergency room are obese or overweight 1) . Obesity may be related to the steroidresistant asthma. Consumption of a highfat diet has been shown to lead to lipid accumulation and inflammatory signaling in key neuronal subsets involved in the regulation of biochemical resistance to insulin, leptin, and other regulatory hormones and nutrient signals 2) . In order to understand the effect of dietary fat on obesity predisposition, we sought to identify molecular metabolic regulators that may be lipid sensitive. Peroxisome proliferator activated receptor (PPAR) γ is member of the PPAR family of nuclear receptors, a class of lipid activated transcription factors belonging to the nuclear receptor superfamily 2) . Current evidence suggests that obesity related changes in the production of adiposederived cytokines, adipokines, may modulate asthma. Alterations in the production of the adipo kines such asleptin and adiponectin could play a critical role in mediating airway inflammation and AHR 3) . PPARs are a family of ligandactivated transcription factors belonging to the nuclear hormone receptor family and related to retinoid, glucocorticoid, and thyroid hormone receptors 4) . The presence of PPARs has been demonstrated in a variety of cells associated with lung inflammation 5) . The widespread dis tribution of PPAR in the airway suggests that they may play important roles in both lung health and disease 6) . PPARs can be involved in the inflammatory cascade of asth ma, and treatment with PPAR agonists may reduce airway in flammation 4) . The activation of PPAR γ and PPARα is thought to downregulate proinflammatory gene expression and inflam matory cell functions 4) . PPAR γ ligands inhibit the release of proinflammatory cytokines from activated macroph ages, airway epithelial cells, and eosinophils, and decrease AHR, basement membrane thickness, collagen deposition, and eosinophilia in murine models of asthma 7) . There have been a few studies for the effect of PPAR γ agonist on airway inflammation in asthmatics, however there is no data on obesity, especially on obese asthma. The presents study aimed to compare the mRNA levels of lung PPAR γ and PPARα among lean and obese mice with and without ovalbumin (OVA) challenge and investigate the effect of rosiglitazone on cytokines related to airway inflammation and airway respon siveness.
Materials and methods
We developed a mouse model of chronic asthma with or without obesity. Mice were divided into 7 groups: control group, lean OVAchallenged groups with (A) and without (B) rosiglitazone, obese groups with (C) and without (D) rosiglitazone, and obese OVAchallenged groups with (E) and without (F) rosiglitazone. Each group was comprised of 6 mice. The animal experimental protocol was approved by the Animal Subjects Committee.
Sensitization and antigen challenge protocol

1) Obese model
Sixweekold female C57BL/6J mice (Central Lab. Animal Inc., Seoul, Korea) were fed a highfat diet in which 45% of the calories are derived from fat (Feedlab, Guri, Korea) for a period of 16 weeks. Food intake and body weight were measured every 7 days during the study period. Mice were allowed free access to water and food and housed 4 per cage in a temperaturecontrolled room with a 12:12hour lightdark cycle. Nonobese mice were given a standard diet. Rosiglitazone was administered with diet in 0.01% concentration.
2) Chronic asthma model Sixweekold female C57BL/6J mice were immunized by subcutaneous injection on days 0, 7, 14, and 21 with 25 μg of OVA (grade V; SigmaAldrich Co., St. Louis, MO, USA) adsorbed to 1 mg of aluminum hydroxide (SigmaAldrich Co.) in 200 μL of phosphatebuffered saline (PBS). Intranasal OVA challenges (20 μg/50 μL in PBS) were administered on days 27, 29, and 31 under isoflurane anesthesia. Intranasal OVA challenges were repeated twice per week until week 18 of the study period. Age and sexmatched control mice were treated the same way with PBS but without OVA. Mice were sacrificed 24 hours after the final OVA challenge, and bronchoalveolar lavage (BAL) and lung tissues were obtained.
3) Measurement of AHR AHR was assessed by a singlechamber wholebody plethys mograph (Allmedicus, Anyang, Korea). The enhanced pause (Penh) was used to monitor airway responsiveness. In the plethysmograph, mice were exposed for 3 minutes to nebulized PBS to establish baseline Penh values, and were subsequently exposed to increasing concentrations of nebulized methacholine (3-50 mg/mL; SigmaAldrich Co.) in PBS using an Aerosonic ultrasonic nebulizer (DeVilbiss, Somerset, PA, USA). Following each nebulization, recordings were taken for 3 minutes. The Penh values measured during each 3minute sequence were averaged and are expressed for each methacholine concentration.
4) Analysis of cells in BAL fluid
Mice were sacrificed after measuring AHR. The trachea was exposed and cannulated with silicone tubing attached to a 23gauge needle on a 1 mL syringe. After the instillation of 1 mL of sterile PBS into the lung, the BAL fluid was withdrawn. The BAL fluid was stained with a hematology analyzer, XE2100 (Sysmex, Kobe, Japan) after cytospinning (7 minutes at 2,000 rpm). Total cell count was performed using a hemacyto meter.
Data analysis
Results for each group were compared by analysis of variance, followed by Dunn's multiple comparison of means. SPSS ver. 10.0 (SPSS Inc., Chicago, IL, USA) was used for analysis. A P value of <0.05 was considered statistically significant. All results are given as mean±standard error of the mean.
Results
Effect of high-fat diet on body weight
Obese groups fed 45% highfat diet with and without OVA challenge weighed significantly more than other groups fed a normal diet. At the end of the study, mice in group C and D reached 27.8 g and 27.7 g, while control mice weighted 22.5 g, and 23% (9.6 g weight gain) and 24% (9.9 g weight gain) more weight gain than that of control group (4.5 g weight gain), respectively (P<0.05). Groups E and F gained more weight by 16% (8.3 g weight gain) and 14% (7.7 g weight gain) compared to control group, respectively (P<0.05). Groups A and B mice showedno difference in weight (4.5 g and 2.7 g weight gain, re spectively) compared to control mice (Fig. 1 ).
Airway inflammation
Total cell numbers and macrophage numbers in BAL fluid increased significantly in groups A to F mice compared to the control group (P<0.05). Groups A, B, E, and F mice also showed a significant increase in total cell and macrophage numbers compared to groups C and D mice (P<0.05). Groups A, B, E and After counting 400 leukocytes on the slide by light microscopy, the percentage of eosinophils, neutrophils, lym phocytes, and macrophages were calculated. Supernatants were stored at 70℃.
5) Analysis of vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β in BAL fluid
VEGF and TGFβ concentrations were measured using enzyme linked immunosorbent assay kit (R&D, Minneapolis, MN, USA) in BAL fluid according to the manufacturer's in structions.
6) RNA isolation and real-time reverse transcription-polymerase chain reaction (RT-PCR)
Lung tissues were analyzed by realtime PCR for leptin, leptin receptor, adiponectin, adiponectin receptor (Adipor1 & Adipor2), VEGF, TGFβ, and TNFα. Total RNA was isolated from lung tissue using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA, at a concentration of 2 μg, was reversetranscribed with Moloney murine leukemia virus reverse transcriptase (MMLVRT) and oligo 8) 12-18 primer (Invitrogen), to generate cDNA. Briefly, RNA was denatured for 10 minutes at 72℃, then immediately placed on ice for 5 minutes. Denatured RNA was mixed with MMLVRT, MMLVRT buffer, and dNTP mixture, and incubated for 1 hour at 42℃. . Each cycle consisted of denaturation at 94℃ for 15 seconds, annealing at 55℃ for 10 seconds, and extension at 72℃ for 20 seconds. Quantification was performed using the com parative 2(delta delta Ct) method; expression levels for the target genes were normalized to the βactin of each sample.
Fig. 1.
Effect of high-fat diet on body mass. Mice fed a high-fat diet (groups C, D, E, and F) weighed significantly more than control mice, whereas mice fed a normal diet (groups A and B) showed no difference in weight compared to control mice at after 18 weeks of the study period. Group A, lean mice with ovalbumin (OVA) challenge; group B, rosiglitazone-treated lean mice with OVA challenge; group C, obese mice without OVA challenge; group D, rosiglitazone-treated obese mice without OVA challenge; group E, obese mice with OVA challenge; and group F, rosiglitazone-treated obese mice with OVA challenge.
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Leptin and leptin receptor mRNA levels increased in groups C and E mice compared to control mice, and rosiglitazone de creased leptin and leptin receptor mRNA levels in both mice (groups D and F). However, administration of rosiglitazone showed increased expression of leptin and leptin receptor mRNA levels in group B mice compared to group A mice.
Adiponectin mRNA levels increased significantly in group A mice compared to control mice and showed a tendency of F mice had significantly increased number of eosinophils in the BAL fluid compared to those in the control group (P<0.05), whereas groups C and D mice showed no significant increase in eosinophils compared to control group. Mice in groups C, D, E, and F showed significant increases in neutrophil numbers in BAL fluid compared to control mice (P<0.05). Rosiglitazone treatment didn't affect cell numbers in BAL fluid compared to notreatment in each group (Fig. 2) .
AHR to methacholine
Increasing doses of methacholine induced an increase in airway resistance in all types of mice. The Penh increase was higher in groups A, B, E and F mice than in control mice, re vealing the induction of AHR in OVAchallenged mice. How ever, groups C and D mice didn't show AHR. Rosiglitazone treatment did not affect AHR in each type of mice with no ro siglitazone treatment (Fig. 3). 4. Expression of PPAR-α, PPAR-γ , leptin, leptin receptor and adiponectin mRNA in lung tissue of mice
To assess the effect of obesity on lung inflammation and expression of adipokines in mice, we measured mRNA levels of PPARα, PPAR γ , leptin, leptin receptor, adiponectin, adipo nectin receptor, VEGF, TNFα and TGFβ in lung tissue of mice by real time PCR.
Expression of PPARα and PPAR γ increased significantly in group E mice compared to control mice, which decreased signifi cantly when rosiglitazone was treated (group F). There were no differences in PPARα and PPAR γ expressions in groups A, B, C, and D mice compared to control mice (Fig. 4A ). Mice in groups A and B showed airway reactivity at methacholine dose of 12.5 mg/mL, group E mice at 25 mg/mL, and group F mice at 50 mg/mL compared to control mice. However, mice in groups C and D did not show airway hyperresponsiveness compared to control mice. group A, lean mice with ovalbumin (OVA) challenge; group B, rosiglitazone-treated lean mice with OVA challenge; group C, obese mice without OVA challenge; group D, rosiglitazone-treated obese mice without OVA challenge; group E, obese mice with OVA challenge; and group F, rosiglitazone-treated obese mice with OVA challenge. *P<0.05 vs. control.
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decrease in group C mice. Administration of rosiglitazone in creased adiponectin mRNA levels in group D mice compared to group C mice, while it showed decreased tendency in group B mice compared to group A mice (Fig. 4B ).
5. VEGF, TNF-α, and TGF-β levels in BAL fluid and mRNA expression in lung tissue of mice VEGF mRNA levels increased significantly in groups A, C, and E mice compared to control mice, which augmented more when rosiglitazone was administered (groups B, D, and F, respectively) compared to no rosiglitazone treatment. Lung mRNA levels of TNFα and TGFβ increased significantly in groups C and E mice compared to control mice. Rosiglitazone also increased TNFα mRNA levels in group F mice compared to group E mice, however decreased TGFβ mRNA levels in group D mice compared to group C mice (P<0.05) (Fig. 5A) .
VEGF levels in BAL fluid were also higher in groups A, C, and E mice than in control mice, which increased significantly in rosiglitazonetreated mice (groups B, D, and F, respectively). Concentration of TGFβ in BAL fluid augmented in groups C and E mice compared to control mice, which decreased signifi cantly in group D mice compared to group C mice (Fig. 5B, C) .
Discussion
We compared PPAR γ and PPARα mRNA levels in lung tissue of mice with OVA challenge and/or obesity, and also investigated the effect of rosiglitazone on lung expressions of PPAR γ and PPARα. PPAR γ and PPARα mRNA levels increased significantly in obese mice with OVA challenge compared to lean mice with OVA challenge and obese mice as well as control mice, and decreased significantly when rosigli tazone was treated.
PPAR γ has been suggested as an indicator of airway inflam mation and remodeling in asthma 9) . A study indicated a positive correlation between PPAR γ expression and airway remodeling in asthma such as subbasement membrane thickening, collagen deposition, and increase of proliferating cells in the epithelium and submucosa area 10) . Intensity of PPAR γ expression in the bronchial submucosa, the airway epithelium and the smooth muscle also showed negative correlation with the forced expir atory volume values. Furthermore, steroids restrained PPAR γ expression in lung tissue 10) . Expression of PPAR γ is also related to obesity. In our previous study, PPAR γ expression also increased in obese rat 11) . We found PPAR γ mRNA level was higher in obese mice with OVA challenge than obese mice or lean mice with OVA challenge, which suggests synergistic effect of obesity and asthma on PPAR γ expression. To our knowledge, there has been no report that investigated PPAR γ and PPARα expressions in obese mice with OVA challenge.
Asthma is a chronic inflammatory airway disease, and obe sity also represents a lowgrade chronic inflammatory state. Considering obese patients have more difficulties in controlling asthma and decreased responsiveness to inhaled corticosteroid 12) , PPAR γ or PPARα agonist can be a good can didate for controll ing difficult asthma in obese asthmatics.
There are a few clinical studies for the therapeutic effect of PPAR γ ligands in asthma. Pioglitazone improved wheezing and coughing in patients with asthma, and asthma symptoms restarted when the pioglitazone treatment was discontinued 13) . Another study shows that rosiglitazone improved lung function, compared with inhaled corticosteroid in steroidresistant smoker with asthma 14) , and PPAR γ agonists reduced the asthma symp toms and levels of Th2 cytokines, adhesion molecules, chemokines, and TGFβ1 in toluene diisocyanateinduced asthma 15) . On the contrary, PPAR γ genetic expression has been shown to be reduced in asthmatic patients after an allergen Fig. 4 . ThemRNA levels of peroxisome proliferator-activated receptor (PPAR)-γ , PPAR-α, leptin, leptin receptor, and adiponectinin the lung tissue of mice and the effect of rosiglitazone treatment. Expression of PPAR-α and PPAR-γ increased significantly in group E mice compared to that in control mice, and it decreased significantly with rosiglitazone treatment in group F mice (A). Leptin and leptin receptor increased significantly in the mice in groups C and E compared to that in control mice, and these decreased significantly with rosiglitazone treatment. Adiponectin increased significantly in group A mice compared to that in control mice, and rosiglitazone augmented adiponectin mRNA level in group D mice compared to that in group C mice (B). Group A, lean mice with ovalbumin (OVA) challenge; Group B, rosiglitazone-treated lean mice with OVA challenge; Group C, obese mice without OVA challenge; Group D, rosiglitazone-treated obese mice without OVA challenge; Group E, obese mice with OVA challenge; and Group F, rosiglitazone-treated obese mice with OVA challenge. *P<0.05 vs. control. † P<0.05 vs. each group of mice without rosiglitazone treatment. challenge, and inversely related to airway inflammation 16) . In mature adipocytes, PPAR γ interacts with several coactivators with chromatin modifying activities, repress and enhance its transcriptional activity 17) . Although PPAR γ and PPARα lung expressions didn't increase significantly in mice with OVA challenge and with obesity, we found a tendency of in crease. As a result, rosiglitazone administration decreased the lung PPAR γ and PPARα mRNA levels in mice with OVA challenge. We can figure out the possibility of significance with the increase of study subjects in the future study.
The direct mechanism for the relationship between obesity and asthma has not been established yet. Leptin is a hormone secreted preferentially by adipose tissue, exerting pleiotropic effects such as body weight homeostasis, reproduction and hematopoiesis 18) . Leptin acts as a proinflammatory cytokine, and its blood level is elevated in obese people. Leptin receptor is expressed in airway smooth muscle 19) , and leptin promoted VEGF release by human airway smooth muscle cells 20) . In this study, leptin as well as leptin receptor demonstrated increased mRNA levels in obese mice with and without OVA challenge, which decreased with rosiglitazone. However, they didn't show significant increase in mice with OVA challenge compared to control mice, and there was no difference in the expression of leptin and leptin receptor between obese mice with and without OVA challenge. Rosiglitazone administration to the preadipocytes isolated from obese mice, resulted in the diffe rentiation into mature adipo cytes. The inhibitory effect of leptin on rosiglitazone induced adipocyte differentiation was also accompanied by the decreased expression of adipogenic transcription factors. Rosiglitazone was decreased in the presence of leptin 18) . Leptin may be related to obesity itself, not asthma, and may not be a contributing factor for poorly controlled asthma in obese asthmatics. There has been no data onthe effect of rosiglitazone on leptin regulation in asthma. Contrary to our study, another study demonstrated rosiglitazone increased leptin levels in obese mice, while decreased leptin levels in lean mice 3) . However, they tried short Fig. 5 . The mRNA levels of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β, and tumor necrosis factor (TNF)-α in the lung tissue of mice and the effect of rosiglitazone in the bronchoalveolar lavage (BAL) fluid. VEGF expression in the lung increased significantly in the mice in groups A, C, and E and was augmented significantly after rosiglitazone treatment. TNF-α and TGF-β expression in the mice in groups C and E increased significantly compared to that in control mice. TNF-α expression was augmented with rosiglitazone treatment in group F mice compared to that in group E mice, while TGF-β expression decreased significantly in group D mice compared to that in group C mice (A). VEGF concentration in the BAL fluid was higher in the mice in groups A, C, and E than in control mice and increased significantly in each group of mice with rosiglitazone treatment (groups B, D, and F). TGF-β level in the BAL fluid was higher in the mice groups C and E than in control mice and decreased signifi cantly in group D mice with rosiglitazone treatment (B and C). Group A, lean mice with ovalbumin (OVA) challenge; group B, rosiglitazone-treated lean mice with OVA challenge; group C, obese mice without OVA challenge; group D, rosiglitazone-treated obese mice without OVA challenge; group E, obese mice with OVA challenge; and group F, rosiglitazone-treated obese mice with OVA challenge. *P<0.05 vs. control. † P<0.05 vs. each group of mice without rosiglitazone treatment. Adiponectin may play an antiinflammatory role in obesity related diseases 21) . Adiponectin receptors are expressed in airway smooth muscle 20) . In this study, lung expression of adiponectin increased significantly in mice with OVA challenge, and decreased in obese mice. However, there was no significant difference in obese mice with OVA challenge compared to control mice. Until now, there has been no data which investi gated the lung expression of adiponectin in obese mice with OVA challenge. Lung adiponectin may not be a major factor to regulate the airway inflammation in obese asthmatics.
Proinflammatory cytokines such as TNF, TGF, and VEGF are increased in obesity. They are also an important cytokines in regulating airway inflammation in asthma 20, 22, 23) . We found augmented lung expression of VEGF, TNFα, and TGFβ in both obese mice with and without OVA challenge, and VEGF mRNA level also increased in lean mice with OVA challenge. However, there was no synergistic increase of cytokine expressions in obese mice with OVA challenge compared to lean mice with OVA challenge or obese mice. In this study, rosiglitazone enhanced lung VEGF mRNA level in all types of mice, and TNFα mRNA level in obese mice with OVA chal lenge. This is supported by another study with murine model with chronic asthma, which shows increased VEGF and TGFβ levels in BAL fluid of ciglitazonetreated asthma mice 24) . However, other studies showed PPAR agonists decreased serum VEGF levels and lung expression of TGFβ 7, 25) , and reduced expression of TNFα in adipocytes ofobese mice treated with the PPAR γ agonist troglitazone 26) . We can assume VEGF, TNFα, and TGFβ are not major contributing cytokines regulated by rosiglitazone in obese asthmatics. There has been no data on the effect of rosiglitazone on cytokine expressions in obese asthmatics.
This study was limited by relatively small number of subjects and no measurement of AHR and airway inflammation. How ever, this is the same method to develop chronic asthma model in mice 24) . And we administered rosiglitazone into the diet, not into the airway. The method and type of PPAR γ agonist as well as the duration of administration can make difference. However, there has been only a few studies using murine model of obese asthmatics, and to our knowledge, this is the first study comparing lung expression of PPAR, adipokines, and cytokines according to obesity and OVA challenge. Taken together, this study suggests that PPARα and PPAR γ lung expression is augmented in obese mice with OVA challenge, and PPAR γ agonist dose not downregulate VEGF, TNFα, and TGFβ expressions in lung tissue of obese asthma.
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